Part 2 of MOXIe was an international, multi-center, double-blind, placebo-controlled Phase 2 trial of omaveloxolone in patients with Friedreich’s ataxia.
Disclaimer
Omaveloxolone is an investigational drug. Safety and efficacy have not been established by any regulatory agency.